DAY101-102: Pan-RAF Inhibitor DAY101 for Patients with Relapsed/Refractory MAPK-Altered Solid Tumors
Condition: Solid Tumors
Sponsor: Day One Biopharmaceuticals, Inc.
DAY101-102: A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors and MAPK Pathway Aberrations
Oral pan-RAF inhibitor DAY101 alone or in combination with oral MEK1/2 inhibitor pimasertib
Advanced or metastatic solid tumor with BRAF fusion, CRAF/RAF1 fusion, or CRAF/RAF1 amplification. Eligible patients will have progressed on/after or not be suitable for any standard of care therapy known to confer clinical benefit in their tumor type.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.